JP2016531878A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531878A5 JP2016531878A5 JP2016518708A JP2016518708A JP2016531878A5 JP 2016531878 A5 JP2016531878 A5 JP 2016531878A5 JP 2016518708 A JP2016518708 A JP 2016518708A JP 2016518708 A JP2016518708 A JP 2016518708A JP 2016531878 A5 JP2016531878 A5 JP 2016531878A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pain
- inflammation
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 206010061218 Inflammation Diseases 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- XXJWXESWEXIICW-UHFFFAOYSA-N 2-(2-Ethoxyethoxy)ethanol Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Chemical group CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- 208000006641 Skin Disease Diseases 0.000 claims 2
- YYGNTYWPHWGJRM-RUSDCZJESA-N Squalene Natural products C(=C\CC/C(=C\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\C)/C)/C YYGNTYWPHWGJRM-RUSDCZJESA-N 0.000 claims 2
- 201000004624 dermatitis Diseases 0.000 claims 2
- 231100000406 dermatitis Toxicity 0.000 claims 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- URZHQOCYXDNFGN-UHFFFAOYSA-N 2,4,6-trimethyl-2,4,6-tris(3,3,3-trifluoropropyl)-1,3,5,2,4,6-trioxatrisilinane Chemical compound FC(F)(F)CC[Si]1(C)O[Si](C)(CCC(F)(F)F)O[Si](C)(CCC(F)(F)F)O1 URZHQOCYXDNFGN-UHFFFAOYSA-N 0.000 claims 1
- OLOSVFFOXWXCPF-UHFFFAOYSA-N 3-benzylsulfonylpropanenitrile Chemical compound N#CCCS(=O)(=O)CC1=CC=CC=C1 OLOSVFFOXWXCPF-UHFFFAOYSA-N 0.000 claims 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 1
- 208000003432 Bone Disease Diseases 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- 206010008685 Chondritis Diseases 0.000 claims 1
- 208000010247 Contact Dermatitis Diseases 0.000 claims 1
- 208000008313 Contusions Diseases 0.000 claims 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 210000003195 Fascia Anatomy 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 210000001503 Joints Anatomy 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010024453 Ligament sprain Diseases 0.000 claims 1
- 210000003041 Ligaments Anatomy 0.000 claims 1
- 210000003205 Muscles Anatomy 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 229960003921 Octisalate Drugs 0.000 claims 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Octyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 claims 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 229940031439 Squalene Drugs 0.000 claims 1
- 235000019486 Sunflower oil Nutrition 0.000 claims 1
- 206010043234 Tendon disease Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 210000002435 Tendons Anatomy 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- -1 capric acid triglyceride Chemical class 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 231100000080 dermatitis contact Toxicity 0.000 claims 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 201000005569 gout Diseases 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 150000003903 lactic acid esters Chemical class 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 201000010770 muscular disease Diseases 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000001575 pathological Effects 0.000 claims 1
- 230000002093 peripheral Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000001263 psoriatic arthritis Diseases 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000002600 sunflower oil Substances 0.000 claims 1
- 230000002522 swelling Effects 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
Claims (10)
- 医薬上許容される担体、及び、3−ベンジルスルホニルプロピオニトリルの化合物又はその医薬上許容される塩を含む、炎症又は疼痛を治療するための医薬組成物。
- 前記化合物は少なくとも90%(w/w)の純度を有し、そして前記組成物はゲル、クリーム、ローション、軟膏、又はパッチの局所形態である、請求項1に記載の医薬組成物。
- 前記医薬上許容される担体は、乳酸ラウリル、ジエチレングリコールモノエチルエーテル、カプリル/カプリン酸トリグリセリド、サリチル酸オクチル(octisalate)、シリコーン流体、スクアレン及びヒマワリ油からなる群より選ばれる皮膚軟化剤である、請求項2に記載の医薬組成物。
- 前記医薬上許容される担体は、乳酸エステル及びジエチレングリコールモノエチルエーテルからなる群より選ばれる透過性エンハンサーである、請求項2に記載の医薬組成物。
- 前記化合物は少なくとも90%(w/w)の純度を有し、前記組成物は錠剤又はカプセル剤の経口形態である、請求項2に記載の医薬組成物。
- 急性もしくは慢性の腫大、疼痛又は発赤を特徴とする炎症の局所症状の徴候を低減又は緩和する、請求項1に記載の医薬組成物。
- 前記炎症及び/又は疼痛は、筋骨格捻挫、筋骨格挫傷、腱障害、末梢神経根症、骨関節炎、関節変性疾患、若年性関節炎、痛風、強直性脊椎炎、乾癬性関節炎、全身性エリテマトーデス、肋軟骨炎、腱炎、滑液包炎、顎関節症候群及び線維筋痛症からなる群より選ばれる骨格又は筋肉疾患又は病態に関連している、請求項1に記載の医薬組成物。
- 前記炎症及び/又は疼痛は関節、靱帯、腱、骨、筋肉及び筋膜に関連している、請求項1に記載の医薬組成物。
- 前記炎症及び/又は疼痛は、皮膚炎又は乾癬の炎症性皮膚疾患又は障害に関連している、請求項1に記載の医薬組成物。
- 前記皮膚炎がアトピー性皮膚炎又は接触性皮膚炎である、請求項9に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361885428P | 2013-10-01 | 2013-10-01 | |
US61/885,428 | 2013-10-01 | ||
PCT/US2014/058347 WO2015050878A1 (en) | 2013-10-01 | 2014-09-30 | Pharmaceutical use of 3-benzylsulfonylpropionitrile |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016531878A JP2016531878A (ja) | 2016-10-13 |
JP2016531878A5 true JP2016531878A5 (ja) | 2017-11-02 |
JP6457502B2 JP6457502B2 (ja) | 2019-01-23 |
Family
ID=52779078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016518708A Active JP6457502B2 (ja) | 2013-10-01 | 2014-09-30 | 3−ベンジルスルホニルプロピオニトリルの医薬上の使用 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3052475B1 (ja) |
JP (1) | JP6457502B2 (ja) |
CN (1) | CN105636935B (ja) |
WO (1) | WO2015050878A1 (ja) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3437685A (en) * | 1964-07-14 | 1969-04-08 | Dow Chemical Co | Dihalosulfones |
DE3041155A1 (de) * | 1980-10-31 | 1982-06-09 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von 2,3-dichlor-sulfonyl-acrylnitrilen |
WO1983001448A1 (en) * | 1981-10-16 | 1983-04-28 | Abbott Lab | Ad1-(2-benzoxazolyl)hydrazinobdalkyl nitrile derivatives |
ATE185798T1 (de) * | 1994-01-22 | 1999-11-15 | British Biotech Pharm | Metalloproteinaseinhibitoren |
US5902817A (en) * | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
US20030212138A1 (en) * | 2002-01-14 | 2003-11-13 | Pharmacia Corporation | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
US7423064B2 (en) * | 2004-09-24 | 2008-09-09 | Olatec Industries, Llc | Composition for treating bacterial, viral, fungal diseases, inflammation and pain |
US20100221336A1 (en) * | 2007-02-14 | 2010-09-02 | Logical Therapeutics, Inc. | Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor |
KR101849813B1 (ko) * | 2010-12-15 | 2018-04-17 | 오라텍 세라퓨틱스 엘엘씨 | 염증 및 통증 치료용 3-메탄술포닐프로피오니트릴 |
-
2014
- 2014-09-30 EP EP14851100.9A patent/EP3052475B1/en active Active
- 2014-09-30 JP JP2016518708A patent/JP6457502B2/ja active Active
- 2014-09-30 WO PCT/US2014/058347 patent/WO2015050878A1/en active Application Filing
- 2014-09-30 CN CN201480054016.9A patent/CN105636935B/zh active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014503533A5 (ja) | ||
MX2017007874A (es) | Derivado de biarilo como agonista de gpr120. | |
EA201800064A1 (ru) | 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl | |
EA201071298A1 (ru) | Соединение 3-аминокарбазола, фармацевтическая композиция, его содержащая, и способ их получения | |
EA201270824A1 (ru) | Соединения для уменьшения продукции бета-амилоида | |
JP2014218522A5 (ja) | ||
JP2018537513A5 (ja) | ||
JP2016511753A5 (ja) | ||
MX2015016543A (es) | Derivados de biarilo como agonistas de gpr120. | |
JP2017222722A5 (ja) | ||
CY1124710T1 (el) | Κετυλιωμενα λιπαρα οξεα, συστημα για την παρασκευη αυτων και χρηση αυτων | |
RU2016137668A (ru) | Новые производные каннабидиол-хинона | |
BR112013018298A2 (pt) | compostos para a redução da produção de beta-amiloides | |
RU2020101477A (ru) | Фармацевтические композиции, содержащие дглк, и их применение | |
JP2016531878A5 (ja) | ||
JP2016533331A5 (ja) | ||
JP2016539179A5 (ja) | ||
RU2009127747A (ru) | Применение непафенака или его производных для лечения дерматологических расстройств, связанных с нарушением кератинизации, которое может иметь иммуно-аллергическую воспалительную составляющую | |
MX370184B (es) | Composición farmacéutica que comprende fingolimod. | |
MX368641B (es) | Compuestos para el tratamiento de inflamación y dolor. | |
EA201491238A1 (ru) | Новая фармацевтическая композиция флурбипрофена и глюкозамина | |
JP2016538288A5 (ja) | ||
ES2498521A1 (es) | Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad | |
BR112014017544A2 (pt) | fitocomposição para o tratamento de dores relacionadas com doenças das articulações | |
RU2015121239A (ru) | Комбинированная фармацевтическая композиция для лечения болевых синдромов |